Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) has announced a strategic partnership with Duke University to create the first Danaher Beacon for Gene Therapy Innovation. This initiative aims to leverage breakthrough science for advancements in genomic medicines, precision diagnostics, and biomanufacturing. Dr. Aravind Asokan from Duke will lead the project, focusing on improving viral vector manufacturing. The collaboration, which commenced in late October 2022, is set to extend over several years, emphasizing the importance of academic partnerships in driving innovation in gene therapy.
Danaher Corporation (NYSE: DHR) reported strong Q3 2022 results with net earnings of $1.6 billion, or $2.10 per diluted share, marking a 36% increase year-over-year. Revenues rose 6% to $7.7 billion, while non-GAAP adjusted diluted earnings per share increased 7% to $2.56. The company saw a solid 10% growth in non-GAAP core revenues. Operating cash flow was $2 billion, and free cash flow reached $1.7 billion. Looking ahead, Danaher expects high-single digit growth in non-GAAP core revenue for Q4 and the full year 2022.
Summary not available.
Danaher Corporation (NYSE: DHR) has scheduled its third quarter 2022 earnings conference call for October 20, 2022, at 8:00 a.m. ET. This one-hour call will be accessible via webcast on Danaher's website under the Investors section. A slide presentation will accompany the call, and a replay will be available until November 3, 2022. The earnings press release and related materials will be posted at 6:00 a.m. ET on the same day.
Danaher Corporation (NYSE: DHR) announced on September 14, 2022, that its President and CEO, Rainer M. Blair, will discuss the anticipated strong performance of the company in the third quarter 2022 during an investor meeting. The company expects core revenue growth to exceed previous guidance due to increased Cepheid respiratory testing revenue, projected to surpass $500 million compared to the earlier estimate of $325 million. Base business core revenue growth is expected in the high single-digit range.
Danaher Corporation (NYSE: DHR) announced plans to separate its Environmental & Applied Solutions (EAS) segment into an independent, publicly traded entity. This separation, expected to be tax-free for shareholders and completed in Q4 2023, will focus on Danaher's Water Quality and Product Identification businesses. EAS, projected to generate approximately $4.7 billion in revenue in 2021, aims for enhanced investment opportunities with a resilient business model and a dedicated leadership team. Jennifer Honeycutt will serve as CEO of EAS post-separation.
On September 13, 2022, Danaher Corporation (NYSE: DHR) declared a quarterly cash dividend of $0.25 per share for common stock, payable on October 28, 2022, to shareholders of record on September 30, 2022. Additionally, a dividend of $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock was announced, payable on October 15, 2022, also to shareholders recorded by September 30, 2022.
Danaher Corporation (NYSE: DHR) will host a live video webcast of its Bioprocessing Investor and Analyst Meeting on September 15, 2022, at 12:00 p.m. ET. The event will take place at the Cytiva facility in Marlborough, Massachusetts, featuring President & CEO Rainer M. Blair and VP Emmanuel Ligner. Interested parties can access the webcast and presentation slides in the
On July 25, 2022, Beckman Coulter announced a partnership with Massachusetts General Hospital to validate the Monocyte Distribution Width (MDW) biomarker for identifying severe pediatric infections. Funded by BARDA, the multi-center trial focuses on children under 15 with high fevers, aiming to enhance early detection of those at risk for hospitalization. This initiative leverages MDW's existing FDA clearance for adult sepsis, expanding its clinical utility in emergency departments, potentially allowing for quicker, informed treatment decisions without unnecessary testing.
Danaher Corporation (NYSE: DHR) reported its Q2 2022 results, showing net earnings of $1.7 billion or $2.25 per diluted share, a 1.5% decrease year-over-year.
However, non-GAAP adjusted diluted net earnings increased by 12% to $2.76 per share. Revenues rose 7.5% to $7.8 billion, with a core revenue growth of 9.5%. Operating cash flow stood at $2.0 billion, while non-GAAP free cash flow reached $1.7 billion. For Q3, the company expects high-single digit growth in core revenue.